THE BIG INVESTMENTS ON CORONA VACCINES
Serum Institute
₹2,100 crore
It plans to invest another ₹900 cr
Zydus Cadila
₹500 crore
Bharat Biotech
₹300-400 crore
When the first Corona cases surfaced during January and February in Kerala and Mumbai, it was an opportunity for scientists at the Indian Council of Medical Research (ICMR)’s National Institute of Virology (NIV) in Pune to study the virus. Professor Priya Abraham, a renowned pathologist and former head of department of Clinical Virology at Christian Medical College, Vellore, had taken over as the new NIV director a couple of months before. Abraham and her team isolated 11 strains of the virus, making India the fifth country after China, the US, Thailand and Japan to do so. Scientists realised the strains were 99.98 per cent similar to the virus then causing havoc in Wuhan. Vaccine development was a possibility. After completing characterisation, immunological biomarker studies and initial pre-clinical studies such as stability, they planned two animal studies. By March, the vaccine was injected in 20 monkeys and the results were 100 per cent sterilising immunity (the virus will not spread to others and within the body) without a single infection. The trial on Syrian Hamsters (a rodent used in trials because they can have similar viral infections in human) also proved 100 per cent immunity. Within two months, ICMR roped in Hyderabad-based Bharat Biotech as the technical partner and industry collaborator.
This story is from the December 13, 2020 edition of Business Today.
Start your 7-day Magzter GOLD free trial to access thousands of curated premium stories, and 9,000+ magazines and newspapers.
Already a subscriber ? Sign In
This story is from the December 13, 2020 edition of Business Today.
Start your 7-day Magzter GOLD free trial to access thousands of curated premium stories, and 9,000+ magazines and newspapers.
Already a subscriber? Sign In
Look Before You Leap
In 2025, Investors Will Need To Factor In Volatility Across Asset Classes
"Focus on the challenge of each customer"
SHASHANK KUMAR MD & CO-FOUNDER I RAZORPAY Razorpay is India's first full-stack financial solutions company
PEDAL ON THE FUTURE
THE MG WINDSOR EV, WITH ITS FUTURISTIC AND MINIMALIST DESIGN, COMBINES THE BEST OF BOTH WORLDS-COMFORT AND TECHNOLOGY
BREATHE EASY
Whether you're battling allergies, looking to remove pollutants, or simply want to breathe easier, the right air purifier can make a difference
The Taste of India in a Glass
FROM ROYAL LIQUEURS TO DISTILLED MAHUA, INDIAN HERITAGE ALCOHOLIC BEVERAGES ARE HAVING THEIR DAY IN THE SUN
MISSING ADVISORS
INDIA HAS JUST ONE INVESTMENT ADVISOR FOR NEARLY EVERY 200,000 INVESTORS. AT A TIME WHEN RETAIL PARTICIPATION IN THE STOCK MARKETS IS BOOMING, THIS ASSUMES SIGNIFICANCE
TURNING A CORNER
SHARED ELECTRIC MOBILITY START-UP YULU'S SHIFT TO SERVICING THE QUICK COMMERCE SECTOR IS HELPING IT GROW FAST. IT IS NOW FOCUSSING ON IMPROVING ROAD SAFETY FEATURES AS IT TURNS EBITDA POSITIVE
REALITY CHECK
INDIAN STOCK MARKETS PLUNGED BEGINNING OCTOBER FOR A HOST OF REASONS, INCLUDING A FALL IN FII OWNERSHIP. HOW DEEP WILL THE CORRECTION BE?
TRUMP'S TRADE TANGO
The return of Donald Trump as the 47th President of the US has put the global economy on edge. India, too, is unlikely to remain unaffected. How will policymakers meet this latest challenge?
"The essence of the Trump administration will be transactional”
Global investor, analyst, and best-selling author Ruchir Sharma decodes why Donald Trump won the elections, what India should do, the risks, and more
